Higher Incidence of Dermatological Immune-Related Adverse Events in Cancer Patients Treated With Immune Checkpoint Inhibitors vs. Other Treatments: A Trinetx Research Network Study
Author Type(s)
Student
Document Type
Letter to the Editor
Publication Date
12-1-2025
DOI
10.1007/s00403-025-04288-7
Journal Title
Archives of Dermatological Research
Keywords
Cancer treatment, Dermatological adverse events, Immune checkpoint inhibitors, Immune-related adverse events (irAEs), Oncology dermatology, Rash, Stevens-johnson syndrome, Vitiligo
Disciplines
Medicine and Health Sciences
Recommended Citation
Islam, R., Chan, R., Gross, A., Malik, H., Pirzadah, H., Abdelmaksoud, A., Haas, C., Fawzy, M., Toraih, E., & Lipner, S. (2025). Higher Incidence of Dermatological Immune-Related Adverse Events in Cancer Patients Treated With Immune Checkpoint Inhibitors vs. Other Treatments: A Trinetx Research Network Study. Archives of Dermatological Research, 317 (1). https://doi.org/10.1007/s00403-025-04288-7
COinS
